Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 2 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 20 of 38

TitleReference numberPublishedLast updated
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695

Results per page

  1. 10
  2. 25
  3. 50
  4. All